Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia.

Trial Profile

Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2013

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms STAR
  • Sponsors Bayer
  • Most Recent Events

    • 08 Jul 2009 Actual patient number (6) added as reported by ClinicalTrials.gov.
    • 08 Jul 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 16 Jun 2009 Planned end date changed from Oct 2009 to Jun 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top